Name
Ariceum Therapeutics
What We Do
Our lead targeted systemic radiopharmaceutical product, 225Ac-satoreotide tetraxetan (Satoreotide, SSO110), is an antagonist of the somatostatin type 2 receptor (SST2) which is overexpressed in many neuroendocrine tumours. We are developing satoreotide as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of neuroendocrine cancers, certain aggressive tumors, which currently have few treatment options and a poor prognosis. Our second clinical stage therapeutic product, ATT001, is a novel 123-Iodine radiolabeled PARP inhibitor (rPARPi) which is in a Phase 1 clinical study in recurrent glioblastoma patients, an indication of high unmet medical need. Ariceum intends to expand the development of ATT001 into other fast growing PARP expressing tumors. Through our partnership with UCB Pharma, we are exploring new targets to develop first-in-class radiopharmaceuticals to continue expanding our pipeline. Ariceum's subsidiary Theragnostics received FDA approval in Feb 2022 for NEPHROSCAN®, Kit for the Preparation of Technetium Tc 99m Succimer Injection (99mTc-DMSA). Please visit our booth, #1139, if you are interested in learning more.
Categories
PET, PET/CT, PET/MR, Pharmaceuticals, Radiopharmaceuticals, SPECT, SPECT/CT
Address
One Broadway
Cambridge, MA 02142
United States
Cambridge, MA 02142
United States
Twitter (X)